Patents Issued in September 4, 2018
  • Patent number: 10066225
    Abstract: Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are DNA for coding the improved nitrile hydratase, a recombinant vector that contains the DNA, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase. Also provided is a method for producing an amide compound that uses the culture or a processed product of the culture. The improved nitrile hydratase contains an amino acid sequence represented by SEQ ID NO: 50 (GX1X2X3X4DX5X6R) in a beta subunit, and is characterized in that X4 is an amino acid selected from a group comprising cysteine, aspartic acid, glutamic acid, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, serine and threonine.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: September 4, 2018
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Fumiaki Watanabe, Ai Hara, Takanori Ambo, Aya Kitahara
  • Patent number: 10066226
    Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 4, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather Sanders, Hai-Rong Li
  • Patent number: 10066227
    Abstract: The present invention relates to genomic analysis. In particular, the present invention provides methods and compositions for mapping genomic interactions.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 4, 2018
    Assignee: University of Massachusetts
    Inventors: Job Dekker, Josee Dostie
  • Patent number: 10066228
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 4, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • Patent number: 10066229
    Abstract: Disclosed herein are methods, compositions, vectors, and kits comprising an antagonist of a truncated TrkC or a truncated TrkB. Also described herein are methods of treating and/or preventing an otic disease or condition associated with an elevated expression level of a truncated TrkC or truncated TrkB isoform.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 4, 2018
    Assignee: OTONOMY, INC.
    Inventors: Horacio Uri Saragovi, Fabrice Piu
  • Patent number: 10066230
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 4, 2018
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Patent number: 10066231
    Abstract: Materials and methods are provided which allowed for increased expression of a transfected gene of interest in a recombinant host cell.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 4, 2018
    Assignee: CMC ICOS BIOLOGICS, INC.
    Inventor: Howard Robert Grahame Clarke
  • Patent number: 10066232
    Abstract: Provided is a separatome-based peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome of E. coli. The separatome-based protein expression and purification platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the separatome-based protein expression and purification platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies facilitating efficient product purification.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: September 4, 2018
    Assignees: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Ellen M. Brune, Robert R. Beitle, Jr., Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
  • Patent number: 10066233
    Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: September 4, 2018
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Rodolphe Barrangou, Patrick Boyaval, Christophe Fremaux, Philippe Horvath, Dennis Romero
  • Patent number: 10066234
    Abstract: The invention relates to yeast cells modified to express a functional type I RuBisCO enzyme, and a class II phosphoribulokinase. The expression of these enzymes recreates a Calvin cycle in said yeasts in order to enable the yeasts to use carbon dioxide.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: September 4, 2018
    Assignees: Institut National de la Recherche Agronomique, Institut National Des Sciences Appliquees De Toulouse, Centre National de la Recherche Scientifique
    Inventors: Denis Pompon, Frederic Paques, Julie Lesage, Stephane Guillouet, Florence Bonnot, Jillian Marc, Nathalie Gorret, Carine Bideaux, Christel Boutonnet
  • Patent number: 10066235
    Abstract: The present invention relates to methods and compositions for improving the efficiency of Agrobacterium- and Rhizobium-mediated plant cell transformation by use of additional transformation enhancer sequences, such as overdrive or TSS sequences, operably linked to a T-DNA border sequence on a recombinant construct that comprises T-DNA.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: September 4, 2018
    Assignee: Monsanto Technology LLC
    Inventors: Larry A. Gilbertson, Xudong Ye
  • Patent number: 10066236
    Abstract: Disclosed are methods for design and synthesis of siRNA libraries, siRNA libraries produced thereby, siRNA molecules, and uses thereof.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 4, 2018
    Assignee: Syngenta Participations AG
    Inventors: Xiang Huang, Thomas Z. McNeill, Micheal Schweiner
  • Patent number: 10066237
    Abstract: The present invention relates to isolated polypeptides having beta-xylosidase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 4, 2018
    Assignee: Novozymes Inc.
    Inventors: Yu Zhang, Ye Liu, Junxin Duan, Lan Tang, Brett McBrayer
  • Patent number: 10066238
    Abstract: Methods for producing antibodies are provided and include transforming a plant cell with a nucleic acid encoding a heavy chain of an antibody, a light chain of an antibody, and a linking polypeptide connecting the heavy chain to the light chain. The nucleic acid is then expressed in the plant cell, such that, upon expression the linking polypeptide is cleaved to separate the heavy chain from the light chain. Isolated nucleic acid sequences, expression vectors, and transformed plant cells useful for producing the antibodies are also provided. Further provided are methods for treating a viral infection and include the steps of obtaining an antibody produced by the above-described methods and then administering the antibody to a subject.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: September 4, 2018
    Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Nobuyuki Matoba, Adam Husk
  • Patent number: 10066239
    Abstract: The present invention relates to a method of increasing resistance against fungal pathogens of the order Pucciniales, preferably the family Phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an RLK2 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells. Furthermore, the invention relates to transgenic plants, plant parts, and/or plant cells having an increased resistance against fungal pathogens, in particular, pathogens of the order Pucciniales, preferably the family Phacopsoraceae, and to recombinant expression vectors comprising a sequence that is identical or homologous to a sequence encoding an RLK2 protein.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: September 4, 2018
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Holger Schultheiss, Tobias Mentzel, Ralf Flachmann
  • Patent number: 10066240
    Abstract: There are disclosed nucleic acid vectors for use in both gram positive and gram negative bacteria. In embodiments the vectors comprise a prokaryotic expression cassette and in embodiments comprise a eukaryotic expression cassette. In embodiments the vectors encode a hybrid protein comprising a DNA binding domain, a CPP domain and a signal sequence.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: September 4, 2018
    Assignee: Symvivo Corporation
    Inventors: Herbert Alexander Graves, Mark Andrew Fox, Sheetal Raithatha, Umesh Ramachandran
  • Patent number: 10066241
    Abstract: The invention provides delivery methods and compositions for antiviral therapeutics. Methods and compositions are provided for targeted delivery of antiviral therapeutics into cells of interest using, for example, viral vectors such as adenovirus, AAV, and replication incompetent HSV. These and other delivery systems can be used as vehicles to deliver DNA vectors encoding a nuclease or a cell-killing gene. These delivery methods can also be used to deliver naked DNA or RNA, protein products, plasmids containing a promoter that is active only in a latent viral state which drives a cell-killing gene, or other therapeutic agents.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: September 4, 2018
    Assignee: The Board of Trustees of The Leland Stanford Junior University
    Inventors: Stephen R. Quake, Jianbin Wang
  • Patent number: 10066242
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: September 4, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Yannick Doyon, Jeffrey C. Miller
  • Patent number: 10066243
    Abstract: A surfactant-improved ethanol fermentation method comprises adding a nonionic surfactant as a protection agent of yeast cell into a fermentation culture medium, therefore greatly improving survival rate of yeast cells in very high gravity ethanol fermentation liquid and endpoint ethanol concentration. The present invention not only improves the cyclic utilization efficiency of the yeast cells, but also achieves the synchronous recycling of the surfactant and a pH adjusting agent. The process of adding the surfactant during VHG fermentation is simple, which can reduce the consumption of water and energy, effectively reduce the fuel ethanol production cost, and improve the fermentation efficiency.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: September 4, 2018
    Assignee: DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES
    Inventors: Zongchao Zhang, Xiumei Liu
  • Patent number: 10066244
    Abstract: Processes for producing ethanol comprise saccharifying cellulosic material with a cellulolytic enzyme composition and fermenting the saccharified cellulosic material with a fermenting microorganism to produce ethanol. The fermenting organism is Saccharomyces cerevisiae CIBTS1260 (deposited under Accession No. NRRL Y-50973 at the Agricultural Research Service Culture Collection (NRRL), Illinois 61604 U.S.A.) or a fermenting organism that has properties that the same or about the same as that of Saccharomyces cerevisiae CIBTS1260).
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 4, 2018
    Assignee: Novozymes A/S
    Inventors: Liuyang Diao, Kate Brandon Sutton, Yu Jiang, Sheng Yang, Yingmiao Liu, Fenghui Qian
  • Patent number: 10066245
    Abstract: A yeast cell having a reduced level of activity of NAD dependent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has at least one exogenous gene encoding NADP dependent GAPDH and/or has up-regulation of at least one endogenous gene expressing NADP dependent GAPDH, wherein combined expression of the enzymes NADP dependent GAPDH, PDC, ALD, ACS, ACC* and MCR in said host cell increases metabolic flux towards 3-HP via malonyl-CoA compared to an otherwise similar yeast cell lacking said genetic modification.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: September 4, 2018
    Assignee: TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Niels Bjerg Jensen, Irina Borodina, Yun Chen, Jerome Maury, Kanchana Rueksomtawin Kildegaard, Jochen Förster, Jens Nielsen
  • Patent number: 10066246
    Abstract: Recombinant yeast cells contain a reductive TCA pathway from phosphoenolpyruvate or pyruvate to succinate. At least one metabolic step in the pathway includes a reaction of NADPH to produce NADP+. The yeast cell contains at least one exogenous NADPH-dependent gene in the pathway from phosphoenolpyruvate or pyruvate to succinate, preferably an NADPH-dependent malate dehydrogensase or fumarate reducase gene (or both).
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: September 4, 2018
    Assignee: CARGILL, INCORPORATED
    Inventors: Brian J. Rush, Kevin T. Watts, Vernon L. McIntosh, Arlene M. Fosmer, Gregory M. Poynter, Thomas W. McMullin
  • Patent number: 10066247
    Abstract: The invention relates to a process for producing a fuel, in particular a liquid fuel, or another organic product, from a carbon-based matter feedstock, comprising the following steps: a/ gasification of the carbon-based matter feedstock in a first reactor, termed gasifier (1), b/ downstream of the gasification, fermentation of the synthesis gas produced according to step a/, by means of microorganisms, water and nutrients in a second reactor, termed fermenter (2), c/ recovery, downstream of the fermenter, of the microorganisms and of the water, d/ injection of at least a part of the recovered microorganisms and, where appropriate, of at least a part of the recovered water at the inlet (10) of the gasifier.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: September 4, 2018
    Assignee: Commissariat A L'Energie Atomique Et Aux Energies Alternatives
    Inventors: Pierre-Alexandre Setier, Florian Delrue
  • Patent number: 10066248
    Abstract: The present disclosure provides a gene encoding a protein having ?-ketoacyl-ACP synthase activity having at least 60% or more identity with the amino acid sequence set forth in SEQ ID NO:1, the protein encoded by the gene, a method of producing a transformant by transforming a host with the gene, a transformant that is transformed with the gene, and a method of producing a lipid, especially, a lipid containing a medium chain fatty acid or ester thereof, by culturing the transformed host that expresses the gene. In some embodiments, the transformant also has a gene encoding an acyl-ACP thioesterase.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: September 4, 2018
    Assignee: KAO CORPORATION
    Inventors: Shinji Sugihara, Tatsuro Ozaki, Hiroko Endo, Takeshi Saito, Takuto Tojo, Hiroyuki Ohta, Koichi Hori
  • Patent number: 10066249
    Abstract: Provided is a means for producing an acetylated sphingoid base using modified microorganism in the genus Starmerella, particularly Starmerella bombicola. A method for producing an acetylated sphingoid base comprising culturing a microorganism in the genus Starmerella to which a xenogeneic gene encoding a polypeptide having an activity to acetylate a sphingoid base is introduced.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: September 4, 2018
    Assignee: KAO CORPORATION
    Inventors: Kumiko Hirano, Atsuko Hayase
  • Patent number: 10066250
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 4, 2018
    Assignee: Codexis, Inc.
    Inventors: Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
  • Patent number: 10066251
    Abstract: The present invention relates to isolated polypeptides having catalase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: September 4, 2018
    Assignee: Novozymes Inc.
    Inventors: Ye Liu, Junxin Duan, Yu Zhang, Lan Tang
  • Patent number: 10066252
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to have reduced levels or activity of one or more alcohol dehydrogenases or aldehyde reductase thereby increasing the production of vanillin or vanillin beta-D-glucoside.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: September 4, 2018
    Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Esben Halkjaer Hansen, Swee Chuang Lim Hallwyl, Klavs Riishede Hansen
  • Patent number: 10066253
    Abstract: Provided is a method for measuring a blood component amount that can sufficiently and properly correct the blood component amount by measuring an Hct value with high accuracy and high reliability, and a sensor and a measuring device that are used in the method. A method for measuring a blood component amount uses a biosensor to calculate a blood component amount in blood. The biosensor includes the following: a first electrode system having a first working electrode and a first counter electrode; a second electrode system having a second working electrode and a second counter electrode; and a reagent portion arranged in a form that covers at least a part of the first electrode system, but does not cover the second working electrode.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: September 4, 2018
    Assignee: PHC Holdings Corporation
    Inventors: Masaki Fujiwara, Tomohiro Yamamoto
  • Patent number: 10066254
    Abstract: Disclosed are methods of diagnosing constipation and constipation-predominant irritable bowel syndrome by screening for the presence of abnormally high levels of methane and/or methanogenic organisms in a subject.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: September 4, 2018
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Henry C. Lin
  • Patent number: 10066255
    Abstract: Provided is a blood culture treatment technology, including a novel treatment technology of performing pretreatment of a positive blood culture to effectively remove foreign substances such as cells, etc., thereby omitting a subculturing process on a solid medium and realizing rapid selection of antimicrobial agents for patients. The pretreatment method of a positive blood culture sample for bacterial identification and antimicrobial susceptibility testing includes preparing a first liquid culture by centrifuging a portion of a liquid medium including the positive blood culture sample, washing a precipitate thus centrifuged with a solution including sodium chloride, and then suspending the precipitate in the solution including sodium chloride, and preparing a second liquid culture by passing the first liquid culture thus prepared through a pretreatment filter including a mesh structure.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: September 4, 2018
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yeon Joon Park, Kang Gyun Park
  • Patent number: 10066256
    Abstract: Methods, compositions, and kits are provided for quantifying a number or frequency of double stranded breaks in the genome of a cell or in the genomes of a population of cells.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 4, 2018
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Yann Jouvenot, Nick Heredia, Viresh Patel, Samantha Cooper, Jen Berman, Eli Hefner
  • Patent number: 10066257
    Abstract: The present invention provides compositions, apparatuses and methods for detecting one or more nucleic acid targets present in a sample. Methods of the invention include utilizing two or more ligation probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive ligation moieties. When such probes have bound to the target in the proper orientation, they are able to undergo a spontaneous chemical ligation reaction that yields a ligation product that is directly detected or that is amplified to produce amplicons that are then detected. The present invention also provides methods to stabilize sample RNA so that degradation does not significantly affect the results of the analysis.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: September 4, 2018
    Assignee: DXTERITY DIAGNOSTICS INCORPORATED
    Inventors: Robert Terbrueggen, Yenbou Liu, John Ray Childers, Jr., Chang Hee Kim, Majid R. Abedi
  • Patent number: 10066258
    Abstract: FRET-labeled compounds are provided for use in analytical reactions. In certain embodiments, FRET-labeled nucleotide analogs are used in place of naturally occurring nucleoside triphosphates or other analogs in analytical reactions comprising nucleic acids, for example, template-directed nucleic acid synthesis, DNA sequencing, RNA sequencing, single-base identification, hybridization, binding assays, and other analytical reactions.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 4, 2018
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Xiangxu Kong, Gene Shen
  • Patent number: 10066259
    Abstract: The invention relates to carrier screening and methods for describing a structural variant, such as a large rearrangement or chromosomal abnormality, in a person's genome using probes that are designed to determine the person's genetic sequence and reveal substitution mutations and small structural variants. Identifying a structural variant may include exposing a nucleic acid to a plurality of probes. Each probe has a linked pair of targeting arms designed to hybridize upstream and downstream of a target in a genome. The method includes hybridizing two of the probes to the nucleic acid and attaching the two probes together to create an inter-probe product as well as detecting the inter-probe product and reporting a structural variant of the genome in the nucleic acid.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: September 4, 2018
    Assignee: Good Start Genetics, Inc.
    Inventors: Athurva Gore, Mark Umbarger
  • Patent number: 10066260
    Abstract: A method of forming a polymer matrix array includes applying an aqueous solution into wells of a well array. The aqueous solution includes polymer precursors. The method further includes applying an immiscible fluid over the well array to isolate the aqueous solution within the wells of the well array and polymerizing the polymer precursors isolated in the wells of the well array to form the polymer matrix array. An apparatus includes a sensor array, a well array corresponding to the sensor array, and an array of polymer matrices disposed in the well array.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 4, 2018
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: David Light, Wolfgang Hinz, Ronald L. Cicero, Christina E. Inman, Paul M. Kenney, Alexander Mastroianni, Roman Rozhkov, Yufang Wang, Jeremy Gray, Marc Glazer, Dmitriy Gremyachinskiy
  • Patent number: 10066261
    Abstract: The present invention relates to a method for amplifying a nucleic acid. More specifically, the present invention relates to a method for amplifying a nucleic acid in a light irradiation dependent manner under a substantially isothermal condition using a photo-responsive nucleic acid.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: September 4, 2018
    Assignees: SYSMEX CORPORATION, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Seigo Suzuki, Hiroya Kirimura, Hiroyuki Asanuma
  • Patent number: 10066262
    Abstract: The present invention provides methods of amplifying a target nucleic acid utilizing duplex primer. The first strand of the primer comprises a random nucleotide sequence of about 6 to about 9 nucleotides in length that is able to hybridize to the target nucleic acid and a tag sequence. The second strand of the primer comprises a sequence complementary to the tag sequence allowing the primer to form a duplex and the ability to bind the tag sequence of the product nucleic acid for further amplification. The resulting nucleic acid produced contains tag sequences on both the 3?- and 5?-termini.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: September 4, 2018
    Assignee: AEGEA BIOTECHNOLOGIES, INC.
    Inventor: Lyle J. Arnold
  • Patent number: 10066263
    Abstract: The present invention relates to methods of nucleic acid analyte detection by PCR. In particular, methods and kits for the detection of a plurality of nucleic acid analytes and the generation of kinetic signatures are provided. Further provided are methods and kits of nested PCR and PCR using limiting primers.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: September 4, 2018
    Assignee: California Institute of Technology
    Inventors: Aditya Rajagopal, Emil P. Kartalov
  • Patent number: 10066264
    Abstract: The present invention is to provide a method for analyzing a target nucleic acid, by which the target nucleic acid can be analyzed rapidly and easily. In order to achieve the above object, the present invention provides a method for analyzing a target nucleic acid in a sample, including the step of: analyzing the target nucleic acid in the sample by bringing the sample into contact with a label and with a primer or probe that can hybridize to the target nucleic acid. The primer or probe is immobilized on a solid phase. The label does not emit light when the primer or probe does not hybridize to the target nucleic acid, whereas the label emits light when the primer or probe has hybridized to the target nucleic acid. The analysis is carried out by detecting the light emitted from the label.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: September 4, 2018
    Assignee: KABUSHIKI KAISHA DNAFORM
    Inventors: Yoshihide Hayashizaki, Masayoshi Itoh, Takahiro Arakawa, Kengo Usui, Sotaro Uemura, Yasumasa Mitani
  • Patent number: 10066265
    Abstract: The invention is directed to methods for determining antigen-specific T cells. In some embodiments, methods of the invention may be implemented by the steps of reacting under interaction conditions one or more antigens with T cells in a plurality of subsets of a tissue sample, such as peripheral blood; sorting antigen-interacting T cells from other T cells; separately sequencing for each subset recombined nucleic acid encoding a segment of a TCR chain from a sample of T cells prior to exposure to antigen and from a sample of T cells isolated based on their interaction with antigen, thereby forming a clonotype profile for the former sample and the latter sample for each subset; and identifying as antigen-specific T cells those T cells associated with a clonotype whose frequency increases in the latter sample relative to its frequency in the former sample.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: September 4, 2018
    Assignee: Adaptive Biotechnologies Corp.
    Inventors: Mark Klinger, Malek Faham
  • Patent number: 10066266
    Abstract: Compositions and methods for the detection and treatment of T1D are provided.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 4, 2018
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Struan Frederick Airth Grant, Jonathan Paul Bradfield, Constantin Polychronakos, Hui-Qi Qu
  • Patent number: 10066267
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Amy Damask, Steven Lewitzky, Michael Rotte
  • Patent number: 10066268
    Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: September 4, 2018
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Gyorgy Petrovics, Shiv Srivastava
  • Patent number: 10066269
    Abstract: The invention provides methods for using the expression levels and subcellular localization of non-coding mitochondrial RNAs to select individuals or subpopulation of individuals for treatment with an anticancer therapy for multiple myeloma. Additional methods provided herein are useful for determining whether an individual in remission for multiple myeloma following successful treatment will be likely to suffer a relapse as well as to identify individuals who have suffered a relapse of multiple myeloma.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 4, 2018
    Assignee: ANDES BIOTECHNOLOGIES GLOBAL, INC.
    Inventors: Claudio E. Villota Arcos, Jaime E. Villegas Olavarria, Veronica A. Burzio Menendez, Luis O. Burzio Eriz
  • Patent number: 10066270
    Abstract: The invention encompasses methods and kits used to detect biomarkers that may be used to predict disease outcome in adrenocortical carcinoma patients.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 4, 2018
    Assignee: The Translational Genomics Research Institute
    Inventors: Kimberly J. Bussey, Michael J. Demeure
  • Patent number: 10066271
    Abstract: This invention relates to methods for identifying maize plants that having decreased MRCV. The methods use molecular markers to identify and to select plants with decreased MRCV or to identify and deselect plants with decreased MRCV. Maize plants generated by the methods of the invention are also a feature of the invention.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: September 4, 2018
    Assignee: AgriGenetics, Inc.
    Inventors: Jennifer L. Hamilton, Juan P. Raimondi, Trisha Borowicz, Cherie Ochsenfeld, James W. Bing
  • Patent number: 10066272
    Abstract: The invention generally relates to human biology discoveries and therapeutic and diagnostic compositions and methods based thereon. More particularly, the invention relates to human homeobox gene VentX and its control of macrophage terminal differentiation and activation, and related therapeutic and diagnostic compositions and methods of use, in particular in connection with inflammatory diseases.
    Type: Grant
    Filed: June 10, 2012
    Date of Patent: September 4, 2018
    Inventors: Zhenglun Zhu, Hong Gao
  • Patent number: 10066273
    Abstract: Operation of a cane preparation unit is disclosed which can include providing a working range for at least one operating variable for a plurality of carriers of a cane preparation unit, estimating energy consumed corresponding to a first plurality of set points for the at least one operating variable, selecting one or more first set points corresponding to reducing (e.g., minimizing) energy consumed for the at least one operating variable as use set points, and operating the cane preparation unit at the use set points.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: September 4, 2018
    Inventors: Arun Kumar M, Babji Buddhi Srinivasa, Abhijit Badwe
  • Patent number: 10066274
    Abstract: A high-strength steel sheet of the present invention is a steel sheet satisfying a predetermined component composition. A metal structure of the steel sheet is composed of polygonal ferrite, high-temperature region generated bainite, low-temperature region generated bainite and retained austenite each having a predetermined area percent, and a distribution using each average IQ of predetermined crystal grains determined by electron backscatter diffraction satisfies Equations (1) and (2) below. According to the present invention, a high-strength steel sheet having excellent ductility and low-temperature toughness can be realized even at a tensile strength of 780 MPa or more. (IQave?IQmin)/(IQmax?IQmin)?0.40??(1) (?IQ)/(IQmax?IQmin)?0.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: September 4, 2018
    Assignee: Kobe Steel, Ltd.
    Inventors: Koji Kasuya, Tadao Murata, Sae Mizuta, Yuichi Futamura